STATE STREET CORP - MERRIMACK PHARMACEUTICALS IN ownership

MERRIMACK PHARMACEUTICALS IN's ticker is MACK and the CUSIP is 590328209. A total of 38 filers reported holding MERRIMACK PHARMACEUTICALS IN in Q4 2021. The put-call ratio across all filers is 8.21 and the average weighting 0.2%.

Quarter-by-quarter ownership
STATE STREET CORP ownership history of MERRIMACK PHARMACEUTICALS IN
ValueSharesWeighting
Q3 2023$2,365,437
+10.5%
191,844
+10.2%
0.00%
Q2 2023$2,141,492
+244.7%
174,105
+244.4%
0.00%
Q1 2023$621,333
-44.5%
50,556
-48.3%
0.00%
Q4 2022$1,119,780
+539.9%
97,712
+109.9%
0.00%
Q3 2022$175,000
-36.8%
46,5560.0%0.00%
Q2 2022$277,000
-5.8%
46,5560.0%0.00%
Q1 2022$294,000
+61.5%
46,5560.0%0.00%
Q4 2021$182,000
-19.1%
46,5560.0%0.00%
Q3 2021$225,000
-24.2%
46,5560.0%0.00%
Q2 2021$297,000
+324.3%
46,556
+316.2%
0.00%
Q1 2021$70,000
-9.1%
11,1850.0%0.00%
Q4 2020$77,000
+71.1%
11,1850.0%0.00%
Q3 2020$45,000
+21.6%
11,1850.0%0.00%
Q2 2020$37,000
+54.2%
11,1850.0%0.00%
Q1 2020$24,000
-31.4%
11,1850.0%0.00%
Q4 2019$35,000
-30.0%
11,1850.0%0.00%
Q3 2019$50,000
-26.5%
11,1850.0%0.00%
Q2 2019$68,000
-12.8%
11,1850.0%0.00%
Q1 2019$78,000
+81.4%
11,1850.0%0.00%
Q4 2018$43,000
-61.6%
11,185
-46.6%
0.00%
Q3 2018$112,000
+14.3%
20,958
+5.1%
0.00%
Q2 2018$98,000
-94.4%
19,939
-90.9%
0.00%
Q1 2018$1,759,000
-21.9%
218,396
-0.6%
0.00%
Q4 2017$2,251,000
-31.1%
219,665
-2.4%
0.00%
Q3 2017$3,269,000225,0070.00%
Other shareholders
MERRIMACK PHARMACEUTICALS IN shareholders Q4 2021
NameSharesValueWeighting ↓
Newtyn Management, LLC 362,335$3,714,0000.57%
Rubric Capital Management LP 410,244$4,205,0000.52%
WITTENBERG INVESTMENT MANAGEMENT, INC. 83,811$859,0000.37%
Yakira Capital Management, Inc. 83,969$861,0000.28%
KEMPNER CAPITAL MANAGEMENT INC. 14,898$153,0000.10%
STONEBRIDGE CAPITAL MANAGEMENT INC 18,550$200,0000.07%
BOGLE INVESTMENT MANAGEMENT L P /DE/ 66,498$681,0000.05%
Cannell & Co. 75,467$774,0000.03%
Trexquant Investment LP 21,347$219,0000.02%
PDT Partners, LLC 58,004$595,0000.02%
View complete list of MERRIMACK PHARMACEUTICALS IN shareholders